SCHEMBL1092284

SCHEMBL1092284

c1ccc2c(CN3CC(Nc4nccc(N5CCCCCC5)n4)C3)c[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.58
HTR1A P08908 11/20 0.55
LMNA P02545 2/20 0.52
HTT P42858 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPK1 P28482 1/20 0.52
JAK2 O60674 1/20 0.51
RAB9A P51151 1/20 0.51
POLB P06746 1/20 0.48
TSHR P16473 1/20 0.48
BCHE P06276 1/20 0.46
CYP2D6 P10635 1/20 0.46
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1090977 0.84 CXCR4 (0.62) CXCR4HTR1ATSHR
SCHEMBL1091085 0.83 CXCR4 (0.59) CXCR4HTR1ALMNAKDM4EALDH1A1
SCHEMBL1091062 0.82 EIF2AK2 (0.46) CXCR4HTR1AJAK2
SCHEMBL2951504 0.81 CXCR4 (0.56) CXCR4HTR1ALMNAHTTKDM4E
SCHEMBL1091394 0.81 CXCR4 (0.63) CXCR4
SCHEMBL1089573 0.80 CXCR4 (0.85) CXCR4
SCHEMBL2950290 0.80 CXCR4 (0.57) CXCR4LMNATSHRALDH1A1
SCHEMBL1090381 0.79 CXCR4 (0.59) CXCR4HTR1A
SCHEMBL1090316 0.79 CXCR4 (0.56) CXCR4HTR1ALMNAHTTKDM4E
SCHEMBL1091137 0.79 CXCR4 (0.60) CXCR4DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HTR1A 1231/4885LMNA 3658/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885HTR1A 1231/4885LMNA 3658/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HTR1A 1231/4885LMNA 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.